Trial Profile
A multinational, multicenter, open-label, single-assignment extension of the MS-LAQ-302 (BRAVO) study, to evaluate the long-term safety, tolerability and effect on disease course of daily oral laquinimod 0.6 mg in subjects with relapsing multiple sclerosis
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 14 Dec 2021
Price :
$35
*
At a glance
- Drugs Laquinimod (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions; Registrational
- Sponsors Teva Pharmaceutical Industries
- 13 Sep 2017 Status changed from active, no longer recruiting to discontinued.
- 21 Jul 2017 This trial has been discontinued in Poland (End date: 2017-05-09)
- 20 Jul 2017 This trial has been discontinued in Spain (End date: 2017-05-09)